Cover Image
市場調查報告書

連環蛋白β-1 (β連環蛋白,CTNNB1) :開發中產品分析

Catenin Beta-1 (Beta Catenin or CTNNB1) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363565
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
連環蛋白β-1 (β連環蛋白,CTNNB1) :開發中產品分析 Catenin Beta-1 (Beta Catenin or CTNNB1) - Pipeline Review, H1 2016
出版日期: 2016年06月22日 內容資訊: 英文 58 Pages
簡介

本報告提供全球各國的連環蛋白β-1 (別名β連環蛋白或CTNNB1) 治療藥的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

  • 簡介
    • 分析範圍
  • 連環蛋白β-1 (β連環蛋白,CTNNB1)的概要
  • 治療藥的開發情形
    • 臨床實驗的各階段
    • 各治療領域
    • 各症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的治療藥
  • 各大學、研究機關開發中的治療藥
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • Dicerna Pharmaceuticals, Inc.
    • iBeCa Therapeutics
    • Marina Biotech, Inc.
    • Propanc Health Group Corporation
    • ScarX Therapeutics
    • Warp Drive Bio, Inc.
  • 藥物簡介
    • 腫瘤用β連環蛋白抑制用反義NRAi寡核苷酸
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的發展情形
    • CEQ-508
    • exisulind
    • nefopam hydrochloride
    • PRP
    • 發炎用小分子
    • 腫瘤用β連環蛋白抑制用小分子 (1)
    • 腫瘤用β連環蛋白抑制用小分子 (2)
    • 腫瘤用β連環蛋白抑制用小分子 (3)
    • 腫瘤用β連環蛋白抑制用合成肽
  • 開發暫停的產品
  • 值得注意的最新趨勢、新聞稿 (共15件)
  • 附錄

圖表一覽

目錄
Product Code: GMDHC0070TDB

Summary

Global Markets Direct's, 'Catenin Beta-1 (Beta Catenin or CTNNB1) - Pipeline Review, H1 2016', provides in depth analysis on Catenin Beta-1 (Beta Catenin or CTNNB1) targeted pipeline therapeutics.

The report provides comprehensive information on the Catenin Beta-1 (Beta Catenin or CTNNB1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Catenin Beta-1 (Beta Catenin or CTNNB1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Catenin Beta-1 (Beta Catenin or CTNNB1)
  • The report reviews Catenin Beta-1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Catenin Beta-1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Catenin Beta-1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Catenin Beta-1 (Beta Catenin or CTNNB1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Catenin Beta-1 (Beta Catenin or CTNNB1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Catenin Beta-1 (Beta Catenin or CTNNB1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Catenin Beta-1 (Beta Catenin or CTNNB1) Overview
  • Therapeutics Development
    • Catenin Beta-1 (Beta Catenin or CTNNB1) - Products under Development by Stage of Development
    • Catenin Beta-1 (Beta Catenin or CTNNB1) - Products under Development by Therapy Area
    • Catenin Beta-1 (Beta Catenin or CTNNB1) - Products under Development by Indication
  • Catenin Beta-1 (Beta Catenin or CTNNB1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Catenin Beta-1 (Beta Catenin or CTNNB1) - Products under Development by Companies
  • Catenin Beta-1 (Beta Catenin or CTNNB1) - Products under Development by Universities/Institutes
  • Catenin Beta-1 (Beta Catenin or CTNNB1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Catenin Beta-1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development
    • Dicerna Pharmaceuticals, Inc.
    • iBeCa Therapeutics
    • Marina Biotech, Inc.
    • Propanc Health Group Corporation
    • ScarX Therapeutics
    • Warp Drive Bio, Inc.
  • Catenin Beta-1 (Beta Catenin or CTNNB1) - Drug Profiles
    • Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEQ-508 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • exisulind - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nefopam hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRP - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Beta-Catenin for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Catenin Beta-1 (Beta Catenin or CTNNB1) - Dormant Projects
  • Catenin Beta-1 (Beta Catenin or CTNNB1) - Featured News & Press Releases
    • Apr 19, 2016: Propanc Files Two More Patents Citing New Compositions of Proenzymes for Cancer Treatment
    • Mar 02, 2016: Propanc Confirms PRP Response to Broad Range of Cancer Indications; Sets Date for Scientific Advice Meeting with UK Regulators
    • Feb 16, 2016: Accel-Rx/BDC make second portfolio investment in ScarX Therapeutics
    • Feb 04, 2016: Propanc Discovers PRP Dramatically Suppresses Cancer Stem Cells
    • Nov 17, 2015: Propanc Demonstrates Significant Anti-Tumor Efficacy in Pancreatic and Ovarian Cancer Preclinical Models; Files Patent Specifying New Therapeutic Target Dose Range
    • Aug 31, 2015: Propanc Receives Patent Approval in Key Jurisdiction
    • Aug 05, 2015: Marina Biotech's CEQ508 Granted FDA Fast Track Designation for Familial Adenomatous Polyposis
    • Jul 09, 2015: Propanc Identifies Positive Signals for Efficacy from Pilot Animal Studies
    • May 06, 2015: Dicerna Announces Potent, Durable Knockdown of Gene Expression in Non-human Primates with DsiRNA-EX Conjugates Being Investigated for Treatment of Primary Hyperoxaluria Type 1 (PH1)
    • May 04, 2015: Dicerna to Present at the 17th Annual TIDES: Oligonucleotide and Peptide Therapeutics From Research through Commercialization Conference
    • Apr 10, 2015: Dicerna Presents New ß-catenin Data from Multiple Tumor Models at the 2015 RNA & Oligonucleotide Therapeutics Meeting at Cold Spring Harbor Laboratory
    • Apr 03, 2012: Marina Biotech Completes Dosing Of Second Cohort In Phase Ib START-FAP Clinical Trial Of CEQ508
    • Feb 29, 2012: Marina Biotech Presents Advances In Oral Delivery Of Nucleic Acids At AsiaTIDES Conference In Tokyo
    • Jan 25, 2012: Marina Biotech Starts Cohort 2 Of Phase Ib START-FAP Clinical Trial Of CEQ508
    • Jun 09, 2011: Marina Biotech Completes Dosing Of First Cohort In Phase Ib/IIa START-FAP Clinical Trial Of CEQ508
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016
  • Pipeline by iBeCa Therapeutics, H1 2016
  • Pipeline by Marina Biotech, Inc., H1 2016
  • Pipeline by Propanc Health Group Corporation, H1 2016
  • Pipeline by ScarX Therapeutics, H1 2016
  • Pipeline by Warp Drive Bio, Inc., H1 2016
  • Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top